Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Mooster, J. L., S. Le Bras, M. J. Massaad, H. Jabara, J. Yoon, C. Galand, B. A. Heesters, et al. 2015. “Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα.” The Journal of Experimental Medicine 212 (2): 185-202. doi:10.1084/jem.20140979. http://dx.doi.org/10.1084/jem.20140979.

Published Version
doi:10.1084/jem.20140979

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462389

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα

Jana L. Mooster,1,3 Severine Le Bras,1,3 Michel J. Massaad,1,3 Haifa Jabara,1,3 Juhan Yoon,1,3 Claire Galand,1,3 Balthasar A. Heesters,2,6 Oliver T. Burton,1,3 Hamid Mattoo,7 John Manis,4,5 and Raif S. Geha1,3

Patients with ectodermal dysplasia with immunodeficiency (ED-ID) caused by mutations in the inhibitor of NF-κB α (IκBα) are susceptible to severe recurrent infections, despite normal T and B cell numbers and intact in vitro lymphocyte function. Moreover, the outcome of hematopoietic stem cell transplantation (HSCT) in these patients is poor despite good engraftment. Mice heterozygous for the IκBα S32I mutation found in patients exhibited typical features of ED-ID. Strikingly, the mice lacked lymph nodes, Peyser’s patches, splenic marginal zones, and follicular dendritic cells and failed to develop contact hypersensitivity (CHS) or form germinal centers (GCs), all features not previously recognized in patients and typical of defective noncanonical NF-κB signaling. Lymphotoxin β receptor (LTβR)-driven induction of chemokines and adhesion molecules mediated by both canonical and noncanonical NF-κB pathways was impaired, and levels of p100 were markedly diminished in the mutant. IκBα mutant→Rag2−/−, but not WT→IκBα mutant, bone marrow chimeras formed proper lymphoid organs and developed CHS and GCs. Defective architectural cell function explains the immunodeficiency and poor outcome of HSCT in patients with IκBα deficiency and suggests that correction of this niche is critical for reconstituting their immune function.

Abbreviations used: AD, autosomal dominant; BAFF, B cell activating factor; CBC, complete blood count; CHS, contact hypersensitivity; EDA, ectodysplasin A; ED-ID, ectodermal dysplasia with immunodeficiency; ES, embryonic stem; FDC, follicular DC; GC, germinal center; HSCT, hematopoietic stem cell transplantation; IκB, inhibitor of NF-κB; IKK, IκB kinase; LTβ, lymphoid tissue inducer; MZ, marginal zone; NEMO, NF-κB essential modulator; NIK, NF-κB inducing kinase; OXA, oxazolone; P, Peyer’s patch; PNA, peanut agglutinin; qPCR, quantitative PCR; TD, T dependent; T1, T independent.

Innate and adaptive immune responses depend on the activation of NF-κB, which has five family members: RelA (p65), RelB, c-Rel, NF-κB1 (p50), and NF-κB2 (p52; Hayden and Ghosh, 2008, 2012; Napetschnig and Wu, 2013). NF-κB dimers are retained in the cytoplasm by inhibitors of NF-κB (IκBs), mainly IκBα in immune cells, which prevent the nuclear translocation of NF-κB. In the canonical NF-κB pathway, used by TLRs, CD40, and receptors for antigen, IL-1, TNF, and ectodysplasin A (EDA), receptor ligation causes activation of the IKK kinase (IKK) complex, which consists of the NF-κB essential modulator (NEMO/IKKγ) and the catalytic subunits IKKα and IKKβ (Bonizzi and Karin, 2004). The activated IKK complex phosphorylates IκBα at Ser 32 and Ser 36, which targets it for polyubiquitination and degradation by the 26S proteasome (Karin and Ben–Neriah, 2000). The released NF-κB dimers (primarily p50/p65) translocate to the nucleus and activate transcription of genes encoding inflammatory cytokines, chemokines, adhesion molecules, and IκBα itself (Hayden et al., 2006; Hayden and Ghosh, 2008). In the noncanonical pathway, used by lymphotoxin β receptor (LTβR), B cell activating factor receptor (BAFF-R), and CD40, NF-κB–inducing kinase (NIK) activates IκKα, resulting in the phosphorylation of p100 (NF-κB2), which is in complex with RelB in the cytoplasm. p100 then undergoes

© 2015 Mooster et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
Defective lymphoid organogenesis in AD ED-ID | Mooster et al.

polyubiquitination and proteasome processing into p52, allowing the p52:RelB dimer to translocate into the nucleus and activate the transcription of genes involved in lymphoid organogenesis (Dejardin et al., 2002; Seymour et al., 2006). There is cross talk between the canonical and noncanonical NF-κB pathways. NIK-dependent activation of IKKα can cause IkBα phosphorylation and degradation, p50:p65 regulates the expression of p100 and RelB, and p100 regulates RelA/p65-containing complexes (Matsushima et al., 2001; Tücker et al., 2007; Shih et al., 2011; Chen et al., 2013).

Ectodermal dysplasia with immunodeficiency (ED-ID) is characterized by sparse hair, conical teeth, reduced number of sweat glands, and susceptibility to severe infections (Kere et al., 1996; Srivastava et al., 2001; Orange and Geha, 2003; Picard et al., 2011). The X-linked form of ED-ID is caused by hypomorphic mutations in NEMO (Puel et al., 2004; Hanson et al., 2008). Autosomal-dominant (AD) ED-ID is caused by heterogeneous hypermutomatic mutations in the IkBα gene NFKBIA (Courttois et al., 2003; Kawai et al., 2012). Six mutations in IkBα, S32I, W11X, E14X, Q9X, M37K, and S36Y, have been identified in AD ED-ID (Courttois et al., 2003; Janssen et al., 2004; McDonald et al., 2007; Lopez-Granados et al., 2008; Ohnishi et al., 2012; Schimke et al., 2013; Yoshioka et al., 2013). In each case, the mutation impairs phosphorylation-driven degradation of the mutant protein, resulting in the sequestration of NF-κB in the cytoplasm (Courttois et al., 2003; McDonald et al., 2007; Kawai et al., 2012). In both forms of ED-ID, activation of the canonical NF-κB pathway is impaired, resulting in ED caused by defective signaling downstream of the EDA receptor, impaired TLR responses, and decreased in vitro B cell response to CD40 ligation (Orange et al., 2005). The severity of the disease correlates with the degree of NF-κB impairment (Orange and Geha, 2003).

Two aspects of the disease phenotype of patients affected by IkBα deficiency have long been a puzzle. The patients suffer from severe, recurrent, and potentially fatal infections despite having normal or elevated T and B cell numbers and intact in vitro T cell function (Courttois et al., 2003; Janssen et al., 2004; McDonald et al., 2007; Kawai et al., 2012). The outcome of hematopoietic stem cell transplantation (HSCT) in these patients is poor in spite of good engraftment of donor lymphoid cells. Of three patients treated with HSCT, only one with the S32I IkBα mutation has survived, but continues to suffer from recurrent infections despite excellent donor lymphoid cell engraftment (Dupuis-Girod et al., 2006; Cancrini, C., personal communication). We have created an IκBα S32I knock-in mouse model of AD ED-ID to gain insights into the disease. The IκBα mutant mouse recapitulates many of the ectodermal and immune abnormalities found in patients with ED-ID. Strikingly, the mutant completely lacked LNs and Peyer’s patches (PPs), and its spleen lacked follicles, marginal zones (MZs), MZ B cells, and follicular DCs (FDCs) and failed to form germinal centers (GCs), all features not previously recognized in patients with ED-ID and typical of defective noncanonical NF-κB signaling. The levels of p100 and noncanonical NF-κB signaling in response to LTβR ligation were decreased in the IκBα mutant. Analysis of BM radiation chimeras demonstrated that the defective lymphoid organogenesis in the IκBα mutant is caused by a defect in nonhematopoietic cells, thus explaining the poor outcome of HSCT in patients with IκBα deficiency.

RESULTS

Mice heterozygous for the S32I mutation in IκBα have ED and impaired IκBα phosphorylation and degradation

The strategy for the generation and identification of the heterozygous IκBα S32I mutant (IκBα mutant) mice is shown in Fig. S1. IκBα mutant mice were born at the normal Mendelian ratio but were significantly smaller in size and weight than their WT littermates (Fig. 1, A and B) and had a 50% survival rate at 8 wk compared with 100% for WT littermates (Fig. 1 C). IκBα mutant mice are missing their third molars, lack guard hairs, and have hypoplastic eccrine glands (Fig. 1, D–F), a phenotype observed in mice with disruption of the Eda gene, mutated in patients with X-linked anhidrotic ED (Srivastava et al., 2001).

Immunoblotting cannot distinguish between WT IκBα and the S32I mutant proteins. We sought evidence for the expression of the mutant protein in heterozygous IκBα mutant mice by examining the susceptibility of IκBα to phosphorylation and degradation after stimulation of fibroblasts with IL-1β. IκBα phosphorylation was significantly weaker in fibroblasts from mutant mice compared with WT littermates (Fig. 1 G). IκBα was mostly degraded by 15 min and completely degraded by 30 min in WT fibroblasts. In contrast, there was markedly less IκBα degradation in the mutant fibroblasts. Similar results were obtained when the fibroblasts were stimulated with TNF and LPS, two other well-known activators of the canonical NF-κB pathway (not depicted).

BMDCs were differentiated from BM cells with GM-CSF and IL-4 and used to examine the response to TLR ligation in a homogeneous population of cells. BMDCs from IκBα mutant mice secreted significantly less TNF in response to TLR1/2, TLR4, TLR7, and TLR9 ligands (Fig. 1 H). Furthermore, up-regulation of Vcam1 (Vascular adhesion molecule 1) and Icam1 (Intercellular adhesion molecule 1) gene expression and of VCAM1 surface expression after TNF stimulation, which are dependent on canonical NF-κB signaling (Dejardin et al., 2002; Winning et al., 2010), was deficient in MEFs from IκBα mutant mice (Fig. 1, I and J). Collectively, these results indicate that the IκBα mutant mice we generated represent a faithful model of ED-ID caused by heterozygous IκBα S32I mutation.

Defective secondary lymphoid organogenesis in IκBα mutant mice

The gross appearance, weight, and cellularity of the thymus and the distribution of thymocyte subsets into CD4+CD8− double-negative cells, CD4+CD8+ double-positive cells, and CD4+ or CD8+ single-positive cells were comparable in IκBα mutant mice and WT littermates (not depicted). BM cellularity and distribution of B220+IgM+CD43+ pro-B, B220+IgM−CD43− pre-B, (B220+IgM+) immature, and
Figure 1. IκBα mutant mice have ED, impaired IκBα processing, and deficient TLR response. (A) IκBα mutant mouse and WT littermate photographed at 3 wk of age. Data are representative of >20 mice per group. (B and C) Growth (B) and Kaplan-Meier survival (C) curves of IκBα mutant mice and WT littermates weighed every 3–4 d and observed daily. Data were derived from 34 mutant mice and 19 WT littermates weighed. (D–F) Photographs of mandibular bones (D) and fur (E) and H&E staining of footpad sections (F) in 6 wk-old IκBα mutant mouse and WT littermate. Red arrows in D show the missing third molars in the mutant mice. Data are representative of four or more mice per group in three independent experiments. Bar, 100 µm. (G) Immunoblot of fibroblast lysates using antibodies to phospho-IκBα or IκBα. Actin was used as a loading control. Pooled results of IκBα phosphorylation at 5 min using three mice per group in three independent experiments. (H) TNF as measured by ELISA in supernatants of BMDCs stimulated with the TLR ligands PamCsk4 (TLR1/2), LPS (TLR4), loxoribine (TLR7), and CpG oligonucleotide (TLR9). Data are representative of four mice per group in two independent experiments for PamCsk4 and LPS and four mice per group in three independent experiments for loxoribine and CpG. (I and J) qPCR analysis of Vcam1 and Icam1 mRNA (I) and flow cytometric analysis of VCAM1 surface expression (J) after TNF stimulation in MEFs from IκBα mutant mice and WT controls. Results in I are expressed relative to unstimulated WT MEFs. Data are representative of three mice per group in three independent experiments. Circles and columns represent means, and bars represent SD in B, C, and G–I. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
(B220^+IgM^+) mature B cell subsets were comparable in IκBα mutant mice and WT littermates (not depicted).

Gross examination revealed no visible cervical, axillary, inguinal, or mesenteric LNs in >15 IκBα mutant mice examined (Fig. 2 A and not depicted). No LN tissue could be detected in hematoxylin and eosin (H&E)–stained serial sections of the inguinal fat pad in IκBα mutant mice (not depicted). To confirm the absence of LNs, we injected mice in the footpad with Evan’s blue dye. Blue-colored lymphatic vessels were readily apparent in both mutant and WT mice. Blue-colored LNs could be detected in the popliteal, inguinal, and paraaortic area in WT mice, but were absent in the mutants (Fig. 2 B and not depicted). Examination of H&E-stained sections of the small intestine revealed no detectable PPs in seven mutant mice that lack both LNs and PPs but have detectable NALT (De Togni et al., 1994; Are et al., 1995; Alimzhanov et al., 1997; Matsumoto et al., 1997; Füttner et al., 1998; Tumanov et al., 2003).

The cellularity of the spleen was greater in IκBα mutant mice than WT littermates, but the difference was not statistically significant (Fig. 3 B). The number of splenic T cells and the distribution of CD4^+ and CD8^+ subsets were comparable between the IκBα mutant mice and WT littermates (Fig. 3 C). Analysis of B cell subsets revealed comparable percentages of B220^+CD93^+ transitional B cells and B220^+CD23^+CD21^+ follicular cells in the two groups but drastically reduced percentages of B220^+CD23^+CD21^+ MZ B cells in mutant spleens (Fig. 3, D and F). The percentages of MZ B cells in the blood were comparable in the mutant and WT littermates (12.1 ± 1.0% in the mutant vs. 10.6 ± 1.8% in WT littermates; n = 3). Given the severe decrease in splenic MZ B cells in the mutant, this result suggests a retention defect but does not rule out a defect in development of MZ cells. IκBα mutant mice had increased numbers of CD11b^+F4/80^+ macrophages but normal numbers of CD11b^+Ly6G^+ granulocytes and CD3^-NK1.1^+ cells and CD11c^- DCs compared with WT littermates (not depicted). The percentages of CD11c^-MHCI^I^B220^+ plasmacytoid DCs and CD11c^-MHCI^I^CD11b^-CD4^+ and CD11c^-MHCI^I^CD11b^-CD8^-CD4^- myeloid DCs were comparable between the two groups, whereas the percentage of CD11c^-MHCI^-CD11b^-CD8^- lymphoid DCs was significantly reduced in the mutant (9.3 ± 0.9% in the mutant vs. 14.8 ± 1.0% in WT littermates; n = 3; P < 0.05).

IκBα mutant mice had a severely disorganized splenic architecture. H&E staining revealed virtual absence of follicles (Fig. 3 G). Immunofluorescence analysis revealed that MOAM^+ macrophages were present in IκBα mutant mice but failed to form the ring structure typical of a MZ (Fig. 3 H). The number of Madcam1^+ cells, which represent the endothelial cells that line the marginal sinus, was decreased, and the organization of these cells was disrupted in the IκBα mutant (Fig. 3 I). FDCM1^+ FDCs were absent from the spleens of the mutant (Fig. 3 J).

**Normal number of lymphoid tissue inducer (LTI) cells but defective response to LTβR ligation and TNF in the IκBα mutant**

Lymphorganogenesis is initiated in the embryo by the interaction of LTI cells with stromal organizer cells, which express LTβR (Rennert et al., 1996; Mebius, 2003; Bénézech et al., 2010). FACS analysis of intestine from embryonic day (E) 17 embryos revealed the presence of higher percentages and numbers of CD45^-CD3^-CD4^-IL-7R^- LTI cells in IκBα mutant mice compared with WT littermates (Fig. 4, A and B), indicating that the IκBα mutation did not interfere with the development of LTI cells.

LTI cells express the LTβR ligand LTα1β2, whereas stromal cells express LTβR. LTβR signaling in stromal cells is essential for lymphoid organogenesis (Fu and Chaplin, 1999). Both the canonical and noncanonical NF-κB pathways are
activated by LTβR and are important for the expression of adhesion molecules and chemokines that drive lymphoid organogenesis, with the noncanonical pathway playing a major role (Miyawaki et al., 1994; Koike et al., 1996; Shinkura et al., 1999; Dejardin et al., 2002; Lo et al., 2006; Vondenhoff et al., 2009). The absence of secondary lymphoid structures in IκBα mutant mice prompted us to examine LTβR signaling in these mice. We stimulated MEFs, as surrogates for stromal cells, with the agonistic LTβR mAb AFH6 and examined the induction of Vcam1 and Icam1 expression, as readouts of canonical NF-κB activation (Dejardin et al., 2002), Cxcl10 (C-X-C motif chemokine 10) expression, as a readout of predominantly canonical NF-κB activation (Hoffmann et al., 2003; Caposio et al., 2007; Shultz et al., 2009), and Madcam1
expression, as a readout of noncanonical NF-κB pathway activation downstream of LTβR (Ganeff et al., 2011). Expression of all these genes after stimulation with LTβR mAb AFH6 was significantly reduced in MEFs from IkBα mutant mice compared with WT controls (Fig. 4 C and not depicted).

Induction of the chemokine genes Ccl19 (C-C motif chemokine 19), Cxcl12, and Cxcl13 after LTβR signaling is important for lymphoid organogenesis and is dependent on the noncanonical NF-κB pathway (van de Pavert et al., 2009; van de Pavert and Mebius, 2010). Because LTβR failed to up-regulate the expression of these genes in WT MEFs (not depicted), we examined their baseline expression in the spleen. Expression of all three chemokine genes was significantly reduced in spleens of IkBα mutant mice compared with WT littermates (Fig. 4 D).

Expression in cell lines of the genes that encode for the noncanonical NF-κB family members p100 and RelB have been reported to be regulated by the canonical NF-κB pathway (Liptay et al., 1994; Bren et al., 2001). The level of p100, but not RelB, was significantly reduced in B cells from IkBα mutant mice (Fig. 4, E and F). NIK levels were comparable in B cells from IkBα mutant mice and WT controls (not depicted). These findings suggest that the S32I IkBα mutation impairs signaling via the noncanonical NF-κB pathway because it results in diminished expression of p100.
in response to immobilized anti-CD3 were comparable in mutant mice and WT littermates (Fig. 5A and B). CD28 ligation increased IL-2 secretion by the mutant T cells, albeit to a significantly lower extent than in WT T cells (Fig. 5B).

Normal intrinsic T cell function but impaired delayed contact hypersensitivity (CHS) in IκBα mutant mice

T cell proliferation upon stimulation with immobilized anti-CD3 with and without soluble anti-CD28 and IL–2 secretion in response to immobilized anti-CD3 were comparable in mutant mice and WT littermates (Fig. 5A and B). CD28 ligation increased IL–2 secretion by the mutant T cells, albeit to a significantly lower extent than in WT T cells (Fig. 5B).
The differentiation of naive CD4+ T cells in vitro under polarizing conditions into Th2 cells was comparable in the mutant and WT littermates, but differentiation into Th1 and Th17 cells was impaired in the mutant (Fig. 5 C). These findings indicate that TCR-driven T cell proliferation, IL-2 secretion, and in vitro Th2 cell differentiation were normal in the mutant, but in vitro Th1 and Th17 cell differentiation were significantly impaired.
After i.p. immunization with OVA, T cells in splenocyte cultures from IkBα mutant mice proliferated normally and secreted IL-2 robustly in response to OVA stimulation (Fig. 5 D). In contrast to the response to i.p. immunization, which involves interaction in the spleen between antigen-presenting DCs and T cells, the T cell response to cutaneously introduced antigen involves interaction in the skin-draining LN between DCs that have captured antigen in the skin and recirculating antigen-specific T cells. IkBα mutant mice sensitized with the hapten oxazolone (OXA) developed significantly less ear swelling with markedly less cellular infiltration and expressed significantly less Ilfng and Il4 mRNA than WT controls (Fig. 5, E and F). Because IkBα mutant mice have partial intrinsic T cell defects, the absence of LNs likely plays a major role in the failure of these mice to mount a CHS response.

**B cell function is modestly decreased in vitro but severely impaired in vivo in IkBα mutant mice**

Proliferation and IgG secretion by purified total splenic B cells in response to stimulation with LPS were modestly, but significantly, reduced in the mutant, whereas IgM secretion was not significantly reduced (Fig. 6, A and B). *Aicda (activation-induced cytidine deaminase)* expression in LPS-stimulated B cells from the mutant was comparable with WT controls, but *Prdm1 (PR domain zinc finger protein 1)* expression was significantly decreased (Fig. 6 C). The proliferation of splenic B cells from IkBα mutant mice in response to stimulation with anti-IgM + IL-4, anti-CD40 + IL-4, LPS + IL-4, and LPS + TGFβ was modestly, but significantly, decreased compared with B cells from WT littermates, as measured by [3H]thymidine incorporation (Fig. 6 D) and CFSE dye dilution (not depicted). IgM, but not IgG, production was significantly decreased in response to LPS + IL-4 and anti-CD40 + IL-4 (not depicted), suggesting that IL-4 may overcome some of the hyposresponsiveness of the B cells to LPS alone. LPS + TGFβ stimulation caused significantly less IgA production by mutant B cells than by WT B cells (Fig. 6 E). BAFF, which activates primarily the noncanonical NF-κB pathway (Claudio et al., 2002), promotes B cell survival and drives modest IgG1 isotype switching in naive B cells (Batten et al., 2000; Castligh et al., 2005). The survival of naive B cells in the presence of BAFF and their IgG1 production in response to BAFF alone or with added IL-4 were significantly reduced in IkBα mutant mice compared with WT littermates (Fig. 6, F and G). This is consistent with the impaired noncanonical NF-κB signaling in the mutant.

Serum IgM levels were comparable in mutant mice and WT littermates, whereas serum IgG levels were significantly decreased, and serum IgA was nearly absent in the mutants (Fig. 6 H). IgA+ plasma cells were absent from the lamina propria of mutant mice (Fig. 6 I).

The antibody responses to the type I T-independent (TI) antigen TNP-LPS, the type II TI antigen TNP-Ficoll, and the T-dependent (TD) antigens OVA and TNP-KLH were all severely diminished in IkBα mutant mice compared with WT controls (Fig. 7, A–C; and not depicted). The IgG antibody response to TD antigens requires GC formation (Rajewsky, 1996). OVA immunization resulted in the robust development of GCs in the spleens of WT mice as indicated by staining for peanut agglutinin (PNA; Fig. 7 D). In contrast, GC development was severely deficient in IkBα mutant mice. OVA immunization caused a significant increase in the percentage of B220+PNA+ and B220+Fas+GL7+ GC B cells in the spleens of WT mice but not IkBα mutant mice (Fig. 7, E and F).

**Reconstitution of IkBα mutant mice with WT BM fails to correct their secondary lymphoid organs and immune defects**

To determine whether the immune phenotype of IkBα mutant mice was intrinsic to lymphocytes, we examined immune function in WT→IkBα mutant chimeras. The same pool of BM cells from CD45.1+ WT mice was used to reconstitute irradiated CD45.2+ IkBα mutant mice and WT littermates. 8 wk after BM transplantation, the two chimeras had comparable numbers of lymphocytes in the blood, with virtually all B cells and >80% of T cells of donor origin (not depicted). Gross examination revealed that LNs and PPs were present in WT→WT control chimeras (Fig. 8, A and B). In contrast, they were not detectable in WT→IkBα mutant chimeras. Splenic cellularity and the percentages of CD3+ , CD4+ , CD8+ , and B220+ cells were comparable in the two chimeras (not depicted). However, follicles and FDCs, which were present in the spleens of control chimeras, were absent from WT→IkBα mutant chimeras (Fig. 8 C), and the percentage of MZ B cells was distinctly decreased in the WT→IkBα mutant chimeras (Fig. 8 D). These findings strongly suggest that nontransferable stromal cells are responsible for the lack of LNs, PPs, splenic follicles, and FDCs and for the decrease in MZ B cells in IkBα mutant mice.

Evaluation of CHS revealed significantly decreased ear swelling, inflammation, and cytokine expression in WT→IkBα mutant chimeras compared with control chimeras (Fig. 8, E–G). WT→IkBα mutant chimeras had impaired antibody responses to TNP-Ficoll and OVA compared with control chimeras (Fig. 8, H and I). OVA immunization resulted in the development of GCs and a significant increase in the percentage of B220+PNA+ GC B cells in the spleens of control chimeras, but not WT→IkBα mutant chimeras (Fig. 8, J and K). The failure of reconstitution with WT BM cells to correct the immune defects in IkBα mutant mice indicates that nonhematopoietic cells are major contributors to the immune deficiency in IkBα mutant mice.

**Secondary lymphoid organs, CHS, and GC formation, but not B cell function, are restored in IkBα mutant→Rag2−/− chimeras**

Rag2−/− mice possess LTI cells, and the cross talk between LTI cells and stromal cells is intact in these mice (Fu and Chaplin, 1999). To determine whether some of the immune defects in IkBα mutant mice are intrinsic to hematopoietic cells, we generated Rag2−/− chimeras. LNs were present and comparable in size, cellularity, and distribution of T and B cells in IkBα mutant→Rag2−/− chimeras and WT→Rag2−/− control chimeras (Fig. 9, A and B). PPs and splenic follicles...
Figure 7. Impaired antibody responses in IκBα mutant mice. (A–C) TNP-specific serum Ig measured by ELISA in mice immunized with TNP-LPS (A) and TNP-Ficoll (B) and OVA-specific serum Ig measured by ELISA in mice immunized with OVA (C). Data represent the mean of duplicate determinations on sera from four to seven mice per group. (D) Spleen sections from immunized mice were stained by histochemistry with anti-B220 or PNA. Bars, 500 µm. Data are representative of six mice per group in three independent experiments. (E and F) Analysis of PNA+ and Fas–GL7+ B cells among the B220+ population of splenic B cells of OVA-immunized mutant mice and WT controls (E) and percentages of these subpopulations in unimmunized and OVA-immunized mice of both groups (F), as analyzed by flow cytometry. Data are representative of three to six mice per group in three independent experiments. Imm, immunization. Lines and columns represent mean, and bars represent SD in A–C and F. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

and FDCs were also present and comparable in size in the two chimeras (Fig. 9, C and D). Furthermore, MZ B cells were present in IκBα mutant→Rag2−/− chimeras, although their number was less than in control chimeras (Fig. 9 E). These findings indicate that the defective lymphoid organogenesis in IκBα mutant mice was not caused by an intrinsic defect in hematopoietic cells.

IκBα mutant→Rag2−/− chimeras mounted a CHS response to OXA comparable with that of control chimeras, as measured by ear swelling, cellular infiltration, and Ifng and Il4 mRNA expression (Fig. 10, A–C). These findings strongly suggest that the lack of CHS in the IκBα mutants is caused by their lack of LNs.

Despite the presence of splenic follicles, FDCs, and MZ B cells, the antibody responses to TNP-LPS, TNP-Ficoll, and OVA were all significantly lower in IκBα mutant→Rag2−/− chimeras than in control chimeras (Fig. 10, D–F). After OVA immunization, the chimeras formed splenic GCs that were comparable in size and number (Fig. 10 G) and had a comparable increase in the percentage of B220+PNA+ cells (Fig. 10 H). Quantitative PCR (qPCR) analysis performed on B220+PNA+ cells revealed that mRNA levels of Aicda and Bcl6, which are expressed by GC B cells, were comparable in the two chimeras. In contrast, mRNA levels of Prdm1 and Xbp1 (X-box–binding protein 1), which drive plasma cell differentiation, were significantly lower in the IκBα mutant→Rag2−/− chimeras than in control chimeras (Fig. 10 I). These results suggest that defective GC formation in IκBα mutant mice is caused by a defect in nonhematopoietic architectural cells rather than in hematopoietic cells. Nevertheless, the B cells from the mutant have an intrinsic defect in terminal differentiation into plasma cells.

**DISCUSSION**

We have generated mice heterozygous for the S32I mutation in IκBα that recapitulate the known features of ED-ID patients who carry the same mutation. Strikingly, these mice had severely defective lymphoid organogenesis caused by a defect in nontransferable architectural cells, a finding not previously appreciated in patients, which may explain their susceptibility to infection despite normal lymphocyte number and in vitro function and their poor response to HSCT.
Figure 8. Secondary lymphoid organs and immune function in WT→IκBα mutant chimeras. (A) Photograph of inguinal fat pad with the vessel junction. The dotted circle indicates the LN at the vessel junction in the fat pad. (B) H&E staining of small intestine sections. The arrow points to a PP in the WT mouse. (C) Spleen sections were stained with H&E (left) and by immunofluorescence for FDCM1, IgD, and IgM (right). (D) Percentage of CD21−CD23+ MZ B cells among B220+ cells in the spleen, as determined by flow cytometry (n = 4–6 mice per group). (E–G) Increase in ear thickness measured by a micrometer (E), representative H&E-stained sections (F), and Il12p40 and Il-4 mRNA expression determined by qPCR (G) 24 h after ear challenge with OXA or vehicle (n = 3–5 mice per group). (H and I) Serum TNP-specific (H) and OVA-specific (I) antibody measured by ELISA in mice immunized with TNP-Ficoll (H) and OVA (I), respectively (n = 5 mice per group). (J) Spleen sections from immunized mice stained by histochemistry with anti-B220 mAb or PNA. Bars: (B) 500 µm; (C left), F, and J 200 µm; (C, right) 100 µm. (K) Percentage of PNA+ B cells among the B220+ population of splenic B cells determined by flow cytometry (n = 3–5 mice per group). Data in A–C and J are representative of three to six mice. Columns and bars in D, E, G–I, and K represent mean and SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Defective lymphoid organogenesis has not been previously appreciated in patients with ED-ID. However, tonsils and cervical LNs have been noted to be absent in at least one of the patients with the S32I IkBα mutation (Courtois et al., 2003; Janssen et al., 2004; McDonald et al., 2007; Lopez-Granados et al., 2008; Ohnishi et al., 2012). Activation of the canonical NF-κB pathway was deficient in these mice, as in the patients (Courtois et al., 2003; McDonald et al., 2007). This was indicated by impaired IkBα phosphorylation and degradation in fibroblasts after stimulation with IL-1, TNF, and LPS. The mutant also showed reduced cytokine production by BMDCs in response to TLR stimulation and decreased up-regulation of ICAM1 and VCAM1 expression by MEFs in response to TNF. Thus, the heterozygous IkBα mutant mice we generated represent a faithful model of humans with hyper-morphic IkBα mutations.

Secondary lymphoid organogenesis was severely defective in the IkBα mutant mouse. The mutant completely lacked LNs and PPs, and its spleen lacked follicles, MZs, MZ B cells, and FDCs. This was surprising because secondary lymphoid organogenesis is relatively well preserved in p50-deficient mice, which only lack inguinal LNs (Lo et al., 2006), and partially preserved in mice deficient in TNF, TNFRI (TNF receptor 1), RANK (receptor activator of NF-κB), or RANKL (RANK ligand), which signal through the canonical NF-κB pathway (Pasparakis et al., 1996, 1997; Körner et al., 1997; Matsumoto et al., 1997; Dougall et al., 1999; Kong et al., 1999; Kim et al., 2000). Instead, the phenotype of IkBα mutant mice closely resembles that of mice deficient in RelB or NIK and mice deficient in LTα, LTβ, or LTβR, which signal through both the canonical and noncanonical NF-κB pathways (Miyawaki et al., 1994; Banks et al., 1995; Weih et al., 1995; Koike et al., 1996; Koni et al., 1997; Füttnerer et al., 1998; Weih et al., 2001; Tumanov et al., 2003; Seymour et al., 2006).

Defective lymphoid organogenesis has not been previously appreciated in patients with ED-ID. However, tonsils and cervical LNs have been noted to be absent in at least one of the patients with the S32I IkBα mutation (Dupuis-Girod et al., 2006). Circulating lymphocyte counts were significantly elevated in IkBα mutant mice, as has been noted in patients with IkBα deficiency (Courtois et al., 2003; Janssen et al., 2004; McDonald et al., 2007; Ohnishi et al., 2012) and in mice that lack LNs and PPs (De Togni et al., 1999; Alimzhanov et al., 1997; Füttnerer et al., 1998).

Lymphoid organogenesis involves activation of both the canonical and noncanonical NF-κB pathways through LTαβ2-LTβR interactions between LTi cells and stromal organizer cells (Mebius, 2003; Vondenhoff et al., 2009; van de Pavert and Mebius, 2010; Roozendaal and Mebius, 2011). LTi cells were present in the IkBα mutant, consistent with previous observations in mice with defects in the canonical NF-κB pathway (Alcamo et al., 2002). As expected, MEFs from the mutant failed to up-regulate *Vcam1*, *Icam1*, and *Ccd10* mRNA expression in response to LTβR ligation, which depends on the canonical NF-κB pathway (Dejardin et al., 2002; Caposio et al., 2007). In addition, they failed to up-regulate the expression of *Makam1*, which depends on the noncanonical pathway downstream of...
for p100 processing into its active product p52 (Dejardin et al., 2002), the impaired noncanonical NF-κB pathway activity in the mutant is likely caused by the decreased p100 levels. In addition to the control of p100 level by the canonical pathway, there is cross talk at other levels between the canonical and noncanonical NF-κB pathways (Matsushima et al., 2001; Shih et al., 2011). The complexity of this talk may account for the variable effects of deficiency in individual components of the canonical NF-κB pathway on lymphoid LTβR (Ganeff et al., 2011). Furthermore, splenocytes from the IκBα mutant expressed significantly less mRNA for the chemokine genes Ccl19, Cxcl12, and Cxcl13, the expression of which depends on the noncanonical NF-κB pathway (Dejardin et al., 2002). We demonstrated that the levels of p100 were markedly reduced in cells from the mutant. This is consistent with previous observations that canonical NF-κB signaling controls p100 levels in cell lines (Liptay et al., 1994; Dejardin et al., 2002; Shih et al., 2011). Because canonical NF-κB activation is not required

**Figure 10.** Defective immune function in IκBα mutant→Rag2−/− chimeras. **(A–C)** Increase in ear thickness measured by a micrometer (A), representative H&E-stained sections (B), and Ifng and Il-4 mRNA expression determined by qPCR (C) 24 h after ear challenge with OXA or vehicle. Data in A–C are representative of five to seven mice per group in three experiments. **(D–F)** Serum TNP-specific (D and E) and OVA-specific (F) antibody measured by ELISA in mice immunized with TNP-LPS (D), TNP-Ficoll (E), and OVA (F), respectively. Data in D–F are representative of a mean of two determinations on sera from 5–10 mice per group. **(G–I)** Spleen sections from immunized mice stained by histochemistry with anti-B220 or PNA. Bars: (B) 200 μm; (G) 25 μm. (H) Percentage of PNA+ B cells among the B220+ population of splenic B cells (n = 3 mice per group) determined by flow cytometry. (I) Aicda, Bcl6, Prdm1, and Xbp1 mRNA expression in B220+PNA+ cells from immunized mice measured by qPCR. Data in G–I are representative of three mice per group in three experiments. Columns and bars in A, C–F, H, and I represent mean and SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Defective lymphoid organogenesis in AD ED-ID | Mooster et al.

The defective antibody response to TNP-Ficoll in the mutant is consistent with the virtual absence of MZ B cells, which play a critical role in the antibody response to type II TI antigens. IgA is virtually absent in patients with the S32I mutation (Courtois et al., 2003; Janssen et al., 2004). Serum IgA levels are low in patients with the I- IgA deficiency. In the IkBα mutant with normal B cell development in the BM and normal B cell numbers in the spleen, but had a severe deficiency in splenic MZ B cells. Proliferation of mutant B cells to LPS was normal, but proliferation to response to BCR, CD40, and TLR4 ligation in the presence of IL-4 was modestly reduced, suggesting a role for IκBα in B cell proliferation supported by IL-4. B cells from the mutant secreted less IgG after LPS stimulation and less IgA after LPS + TGFβ stimulation than control B cells. Expression of Aica was normal, but expression of Pdmi was reduced in LPS-stimulated B cells from the mutant, suggesting a defect in terminal B cell differentiation. B cell survival and IgG1 isotype switching in response to BAFF, which activates NF-κB primarily via the canonical pathway, was impaired in the mutant. Serum IgG levels were decreased in the mutant mice, and serum IgA and intestinal IgA+ cells were virtually undetectable. IgA levels are low in patients with the IκBα S32I mutation (Courtois et al., 2003; Janssen et al., 2004). Serum IgA is virtually absent in Lbr−/− and NIK-deficient mice (Shinkura et al., 1999), and its level is decreased in Nfkb1−/− mice (Snapper et al., 1996) and Rela−/−/Tnfr1−/− mice, which have impaired canonical signaling (Alcamo et al., 2002). Thus, defects in both canonical and noncanonical pathways may underlie the absence of IgA in the mutant.

Antibody responses to TI and TD antigens were severely deficient in the mutant. The defective response to TNP-Ficoll is consistent with the virtual absence of MZ B cells, which play a critical role in the antibody response to type II TI antigens (Balázs et al., 2002; Pillai et al., 2005). Remarkably, despite intact proliferation of splenic T cells in response to OVA stimulation ex vivo, the antibody response of the mutant to i.p. immunization with OVA was virtually absent and was accompanied by a total failure to form GCs. None of the antibody responses were restored in IκBα mutant→Rag2−/− chimeras, despite the restoration of MZ B cells and GC formation with generation of normal numbers of PNA+ B cells, suggesting that an intrinsic defect in terminal B cell differentiation exits in the mutant. This was supported by the observation that the expression by PNA+ cells of Pdmi and Xbp1, which encode two transcription factors required for plasma cell differentiation, was significantly reduced in the IκBα mutant→Rag2−/− chimeras. Thus, the defective antibody response of IκBα mutant mice is two-tiered, involving defective lymphoid organogenesis and an intrinsic defect in terminal B cell differentiation.

Reconstitution of the IκBα mutant with WT BM cells failed to restore lymphoid organogenesis and to correct the immune defects in irradiated IκBα mutant recipients, despite excellent chimerism in the T and B cell lineages. This finding recapitulates the poor results of allogeneic HSCT in patients with IκBα mutations despite the engraftment of donor lymphocytes. Notably, despite 100% chimerism in lymphoid cells, the single patient with the S32I IκBα mutation who has survived HSCT continues to suffer from recurrent infections requiring gamma globulin replacement and has persistent lymphocytosis, no visible tonsilar tissue, and no palpable LNs even during infection (Dupuis-Girod et al., 2006; Cancrini, C., personal communication).

Our findings suggest that defects in architectural nonhematopoietic cells, likely a mesenchymally derived stromal cell, underlie the immune deficiency in patients with ED-ID caused by mutations in IκBα and explain the poor outcome of allogeneic HSCT in these patients. Strategies that correct defective architectural cell function, such as implantation of stromal cell-embedded bio compatible scaffolds to generate LNs (Okamoto et al., 2007), may be valuable in patients with IκBα deficiency.

MATERIALS AND METHODS

Generation of heterozygous IκBα S32I knock-in mice. The arms of the IκBα S32I targeting vector were amplified by PCR from genomic DNA of the C57 embryonic stem (ES) cell line derived from the 129Sv mouse strain. The 2.8-kb 5′ and 3.1-kb 3′ arms were cloned into the pKS-neo-DTAIII vector (a gift from the laboratory of M. Greenberg, Harvard Medical School, Boston, MA), and the nucleic acid G94T mutation was introduced by site-directed mutagenesis (Agilent Technologies) into exon 1 in the 5′ arm, resulting in the amino acid S32I mutation (Fig. S1 A). The linearized targeting construct was electroporated into CJ7 ES cells, which were then selected in 0.4 mg/ml G418 and 10 mg/ml ganci clovir. An ES cell clone containing a disrupted allele and no random integration of the neomycin-resistance gene was confirmed by PCR. Southern blotting (Fig. S1 B) and then injected into 3.5-d-old C57BL/6 blastocysts, and IκBα S32I heterozygous neo mice were obtained by standard methods (Tatsukov et al., 1997). The presence of mutant RNA was confirmed by amplifying cDNA with the primers 5′-CAGGACTGCGG-CATGGAG-3′ and 5′-CTCTCCCGACCTCCTTC-3′, followed by digestion with the restriction enzyme MwoI (Fig. S1 C).

Mice were backcrossed nine generations to C57BL/6 mice from Charles River. All mice were kept in a specific pathogen-free environment in autoclaved...
cages with trimethoprim/sulfamethoxazole and enrofloxacin added to the water to prevent infection. Procedures were performed in accordance with the Animal Care and Use Committee of the Children's Hospital Boston.

**Dermal fibroblast isolation and culture.** Primary dermal fibroblasts were isolated as in McDonald et al. (2007) and grown in RPMI media plus 10% FCS (Hyclone) plus l-glutamine, penicillin, and streptomycin (Invitrogen). Fibroblasts were stimulated with media, 10 ng/ml IL-1, 10 ng/ml TNF (R&D Systems), or 1 mg/ml LPS (Sigma-Aldrich) for the indicated times.

**Western blotting.** Western blotting was performed as previously described (McDonald et al. 2007) using anti-phospho IκBα (Cell Signaling Technology), anti–mouse full-length IκBα (Abcam), and anti-actin (Sigma-Aldrich) according to the manufacturers’ recommendations. Immunoblotting was also performed using anti-p100/p52, RelB, and NIK (Cell Signaling Technology). Sheep anti–mouse horseradish peroxidase–conjugated and sheep anti–rabbit horseradish peroxidase–conjugated secondary antibodies were obtained from GE Healthcare. Quantification was performed using the public domain ImageJ/FIJI software from the National Institutes of Health.

**BMDC isolation and TLR ligand stimulation.** BM was flushed from the femur and tibia of 6–8-wk-old mice, plated in DMEM (Gibco) plus 10% FCS and plus l-glutamine, penicillin, and streptomycin, 10 ng/ml GM-CSF, and 10 ng/ml IL-4. Cells were washed at day 1, replated at day 7, and used for experiments between days 8 and 12. The DC phenotype was confirmed by flow cytometry for CD11c and MHCII and negative for Ly6G. The TLR ligands PAM3CSK4 (TLR1/2), ultrapure LPS from Salmonella minnesota (TLR4), loxoribine (TLR7), and CpG DNA (ODN1826; TLR9) were obtained from InvivoGen.

**MEF isolation and culture.** Primary MEFs were isolated as in Xu (2005) and grown in DMEM plus 10% FCS and plus l-glutamine, penicillin, and streptomycin.

**VCAM1 surface staining.** MEFs were treated for 24 h with 10 ng/ml TNF, dissociated with trypsin/EDTA, and stained with anti-VCAM1 (BioBioscience).

**LN detection by Evan’s blue injection.** LN detection was performed as described in Harrell et al. (2008).

**H&E staining.** Samples of inguinal fat pad, small intestine, nasal cavity, thymus, spleen, and LN were fixed in formalin for 24 h, and then H&E staining of paraffin-embedded cut sections was performed by the Rodent Histopathology and Specialized Histopathology Services cores at the Dana Farber/Harvard Cancer Center (Boston, MA) or by Histo-Scientific Research Laboratories (HSRL, Mt. Jackson, Virginia).

**Complete blood counts (CBCs).** Blood was collected from the facial vein, and CBC analysis was performed by the Animal Research at Children’s Hospital (ARCH) facility.

**FACS analysis.** Single-cell suspensions from spleen, thymus, or BM of 4–6-wk-old mice were stained with FITC, PE, PE-Cy7, APC, PerCP-Cy5.5, Alexa Fluor 700, or APC–eFluor 780–labeled mAbs and analyzed on a FACSCanto (BD). Antibodies to B220, CD3, IgM, CD21, CD23, CD93, CD43, CD4, CD8, GL-7, CD11b, Ly6G, F4/80, NK1.1, CD45, IL-7-R, CD45.1, and CD45.2 were from eBioscience, mAb to Fas was from BD, and FITC-conjugated PNA was from Sigma-Aldrich.

**Immunofluorescence.** Immunofluorescence was performed as described in Carinpa et al. (2009) and Kranich et al. (2008).

**LTI cell isolation from embryonic intestine.** Embryonic intestines were isolated from E17.5 fetuses, incubated in Liberase (Roche) for 1 h at 37°C, and then passed through a 70-µm filter. A portion of the embryos was reserved for genotyping.

**qPCR.** MEFs were stimulated with 2 µg/ml anti-IL-1β, agonist antibody AFH6 (a gift from J. Browning, Biogen Idec, Cambridge, MA) or 10 ng/ml TNF (R&D Systems) for 24 h, and RNA was extracted using the TRIzol (Invitrogen) method. cDNA was synthesized using Script (Bio-Rad Laboratories), and qPCR was performed using TaqMan probes and the 7300 Real-time PCR System (Applied Biosystems).

**Purification and stimulation of splenic T and B cells.** T cells were purified from spleen suspensions using the pan-T cell isolation kit II (Miltenyi Biotec), and 100,000 per 96 wells were plated, along with 300,000 irradiated (3,000 rad) non-T cell APCs purified by the CD90.2 kit (Miltenyi Biotec) using RPMI supplemented with penicillin/streptomycin, Hepes (Gibco), sodium pyruvate, and β-mercaptoethanol. 200,000 cells in 96-well plates were plated for proliferation assays, and 250,000 per 24-well plates for in vitro Ig analysis. Cells were stimulated with 0.1–10 µg/ml LPS (Sigma-Aldrich) or 10 µg/ml LPS, 10 µg/ml anti-µ (Jackson Immuno-Research Laboratories, Inc.), or 500 ng/ml anti-CD40 (eBioscience), alone or in combination with 40 ng/ml IL-4 (R&D Systems). Trinitrated thymidine (PerkinElmer) was added at day 3, and incorporation was assayed after 15–18 h. Supematants from in vitro Ig experiments were analyzed by ELISA on day 6. Aida and Prdm f mRNA expression was assessed by PCR on RNA extracted from 4-d-cultured naive B cells either in medium or plus 10 µg/ml LPS using TaqMan probes. For BAFF-induced responses, naive B cells were prepared from splenocytes by negative selection using a cocktail of biotin-conjugated mAbs to CD43, CD11b, Thy1.2, CD138, IgG1, IgG2a, IgG2b, IgG3, IgA, and IgE (BD) and streptavidin magnetic beads (Invitrogen). Naive B cells were cultured in medium alone or in the presence of 1 mg/ml sBAFF (Alexis) or 50 ng/ml sBAFF + IL-4. To assess cell viability, cells were counted at day 4 in the presence of trypan blue (Sigma-Aldrich), and the percentage of live cells was determined. IgG1 secretion in supematants was analyzed by ELISA on day 7.

**In vitro T helper cell differentiation.** For Th0 conditions, naive CD4+ T cells were sorted by MACS and were stimulated for 5 d with plate-bound antibodies against CD3 (145-2C11; 2 µg/ml; eBioscience) and CD28 (PV-1; 2 µg/ml; BioLegend). For Th2 cell differentiation, 50 ng/ml IL-4 (BioLegend) and 10 µg/ml neutralizing anti–IFN-γ mAb (XMG 1.2; BioLegend) were added. For Th17 cell differentiation, 40 ng/ml IL-6 (BioLegend), 40 ng/ml IL-23 (R&D Systems), 1 ng/ml TGF-β (BioLegend), 10 µg/ml anti–IL-1β (11B11; BioLegend), and 10 µg/ml anti–IFN-γ (XMG1.2; BioLegend) neutralizing antibodies were added. For Th1 cell differentiation, 5 ng/ml IL-12 (BioLegend) and 10 µg/ml anti–IL-4 neutralizing mAbs (11B11; BioLegend) were added.

**Serum Ig levels and antibody responses.** 4–6-wk-old mice were immunized i.p. with 50 µg OVA with Alum (Sigma-Aldrich) in PBS at day 0, boosted at day 14, and bled at days 0 and 21. Mice were immunized i.p. with 25 µg TNP–LPS (Biosearch Technologies) in PBS or with 25 µg TNP–Ficoll (Biosearch Technologies) at day 0 and bled at days 0 and 14. Antigen-specific antibody responses were analyzed by OVA- or TNP-specific ELISA using 96-well plates coated with either OVA- or TNP-conjugated BSA (Biosearch Technologies) at 10 µg/ml in PBS. For serum Ig levels, plates were coated with isotype-specific antibodies (SouthernBiotech). AP-conjugated secondary antibodies (SouthernBiotech) and PNPP (Sigma-Aldrich) were used for ELISA.
Batten, M., J. Groom, T.G. Cachero, F. Qian, P. Schneider, J. Tschopp, Banks, T.A., B.T. Rouse, M.K. Kerley, P.J. Blair, V.L. Godfrey, N.A. Kuklin, D.M. Alimzhanov, M.B., D.V. Kuprash, M.H. Kosco-Vilbois, A. Luz, R.L. Alcamo, E., N. Hacohen, L.C. Schulte, P.D. Rennert, R.O. Hynes, and D. Accepted: 23 December 2014
Submitted: 22 May 2014

The authors declare no competing financial interests.

Submitted: 22 May 2014
Accepted: 23 December 2014

REFERENCES

Alcântara, E., N. Hacohen, L.C. Schulte, P.D. Rennert, R.O. Hynes, and D. Baltimore. 2002. Requirement for the NF-kB family member RelA in the development of secondary lymphoid organs. J. Exp. Med. 195:233–244. http://dx.doi.org/10.1084/jem.20011885

Alimzhanov, M.B., D.V. Kuprash, M.H. Kosco-Vilbois, A. Luz, R.L. Turetskaya, A. Tarakhovsky, K. Rajewsky, S.A. Nedospasov, and K. Pfeffer. 1997. Abnormal development of secondary lymphoid tissue in lympho- toxin-β-deficient mice. Proc. Natl. Acad. Sci. USA. 94:9302–9307. http://dx.doi.org/10.1073/pnas.94.19.9302

Baláz, M., F. Martin, T. Zhou, and J. Kearney. 2002. Blood dendritic cells interact with splenic marginal zone B cells to modulate T-independent immune responses. Immunity. 17:341–352. http://dx.doi.org/10.1016/S1074-7613(02)00389-8

Banks, T.A., B.T. Rouse, M.K. Kerley, P. Blair, V.L. Godfrey, N.A. Kuklin, D.M. Bouley, J. Thomas, S. Kanangat, and M.L. Mucenski. 1995. Lympho toxin-α-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J. Immunol. 155:1685–1693.

Batten, M., J. Groom, T.G. Cachero, F. Qian, P. Schneider, J. Tschopp, J.L. Browning, and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192:1453–1466. http://dx.doi.org/10.1084/jem.192.10.1453

Bénézech, C., A. White, E. Mader, K. Serre, S. Parnell, K. Pfeffer, C.F. Ware, G. Anderson, and J.H. Caamaño. 2010. Ontogeny of stromal organizer cells during lymph node development. J. Immunol. 184:4521–4530. http://dx.doi.org/10.4049/jimmunol.0903113

Bonizzi, G., and M. Karin. 2004. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280–288. http://dx.doi.org/10.1016/j.it.2004.03.008

Bren, G.D., N.J. Solan, H. Miyoshi, K.N. Pennington, L.J. Pobst, and C.V. Paya. 2001. Transcription of the RelB gene is regulated by NF-κB. Oncogene. 20:7722–7733. http://dx.doi.org/10.1038/sj.onc.1204868

Capossi, P., T. Musso, A. Luganimi, H. Ionue, M. Garaglio, S. Landolfo, and G. Gribaudo. 2007. Targeting the NF-κB pathway through pharmacological inhibition of IKK2 prevents human cytomegalovirus replication and virus-induced inflammatory response in infected endothelial cells. Antiviral Res. 73:175–184. http://dx.doi.org/10.1016/j.antiviral.2006.10.001

Curzappa, A., H. Takematsu, H. Liu, S. Dusz, K. Hauler, C. Bo quota, G. Kalloo, M. Connole, H.N. Shi, N. Varki, et al. 2009. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-α-acetyl sialic acid esterase. J. Exp. Med. 206:125–138. http://dx.doi.org/10.1084/jem.20081399

Castigli, E.A., S.A. Wilson, S. Scott, F. Deodugolu, S. Xu, K.P. Lam, R.J. Bram, H. Jabara, and R.S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201:35–39. http://dx.doi.org/10.1084/jem.20032000

Chen, K., E.M. Coomrod, A. Kumanovics, Z.F. Franks, J.D. Durtchi, R.L. Margraf, W. Wu, N.M. Heikal, N.H. Augustine, P.G. Ridge, et al. 2013. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Ann. J. Hum. Genet. 93:812–824. http://dx.doi.org/10.1016/j.ajhg.2013.09.009

Claudio, E., K. Brown, S. Park, H. Wang, and U. Siebensthr. 2002. BAFF- induced NEMO-independent processing of NF-κB 22 in maturing B cells. Nat. Immunol. 3:958–965. http://dx.doi.org/10.1038/ni842

Clauss, F., M.C. Manière, F. Obry, E. Weltmann, S. Hady-Rabia, C. Bodemer, Y. Alemnik, H. Lesot, and M. Schmittbuhl. 2008. Dento-craniofacial phenotypes and underlying molecular mechanisms in hypohidrotic ectodermal dysplasia (HED): a review. J. Dent. Res. 87:1089–1099. http://dx.doi.org/10.1177/0140917608071020

Courtois, G., A. Smahi, J. Reichenbach, R. Döffinger, C. Cancrini, M. Bonnet, A. Puel, C. Chable-Bessua, S. Yamaoka, J. Fennberg, et al. 2003. A hypermorphic InBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112:1108–1115. http://dx.doi.org/10.1172/JCI18714

De Togli, P., J. Goellner, N.H. Ruddle, P.R. Streeter, A. Fick, S. Mariathasan, S.C. Smith, R. Carlson, L.P. Shornick, J. Strauss-Schoenberger, et al. 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lympho toxin. Science. 264:703–707. http://dx.doi.org/10.1126/science.8171322

Dejardin, E., N.M. Dron, M. Delhase, E. Haas, Y. Cao, C. Makris, Z.W. Li, M. Karin, C.F. Ware, and D.R. Green. 2002. The lympho toxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity. 17:525–535. http://dx.doi.org/10.1016/S1074-7613(02)00423-5

Douglas, W.C., M. Glaccum, K. Carriher, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, et al. 1999. RANK is essential for osteoclast and lymph node development. Gene. 23:124–242. http://dx.doi.org/10.1101/gad.13.18.2412

Dupuis-Giroud, S., C. Cancrini, F. Le Deist, P. Palma, C. Bodemer, A. Puel, S. Livaditi, C. Picard, X. Bossuyt, P. Rossi, et al. 2006. Successful allogeneic hemopoietic stem cell transplantation in a child who had anhidrotic ectodermal dysplasia with immunodeficiency. Pediatrics. 118:e205–e221. http://dx.doi.org/10.1542/peds.2005-2061

Fu, Y.X., and D.D. Chaplin. 1999. Development and maturation of secondary lymphoidtissues. Annu. Rev. Immunol. 17:399–433. http://dx.doi.org/10.1146/annurev.immunol.17.1.399

Fütterer, A., K. Mink, A. Luz, M.H. Kosco-Vilbois, and K. Pfeffer. 1998. The lympho toxin-β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity. 9:59–70. http://dx.doi.org/10.1016/S1074-7613(00)80588-9

Gannef, C., E. Remouchamps, L. Boutafali, C. Benezech, G. Galopin, S. Vandepeere, F. Boullenne, S. Ormense, A. Chariot, P. Schneider, et al. 2011. Induction of the alternative NF-κB pathway by lympho toxin.
Hanson, E.P., L. Monaco-Shawver, L.A. Solt, L.A. Madge, P.P. Banerjee, C.M. Gray, C.M., C. Remouchamps, K.A. McCorkell, L.A. Solt, E. Dejardin, J.S. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Koike, R., T. Nishimura, R. Yasumizu, H. Tanaka, Y. Hataba, Y. Hataba, Kere, J., A.K. Srivastava, O. Montonen, J. Zonana, N. Thomas, B. Ferguson, Janssen, R., A. van Wengen, M.A. Hoeve, J.L. Browning, N.H. Ruddle, and R.A. Flavell. 1997. Distinct roles in lymphoid organogenesis for lympho- toxins α and β revealed in lympho toxin-β-deficient mice. Immunity. 6:491–500. http://dx.doi.org/10.1016/S1074-7613(00)80292-7

Kömer, H., M. Cook, D.S. Rimnont, F.A. Lemcke, R.M. Hoek, B. Ledermann, F. Köntgen, B. Fazekas de St Groth, and J.D. Sedgwick. 1997. Distinct roles for lympho toxin-α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27:2600–2609. http://dx.doi.org/10.1002/eji.1830271020

Kranich, J., N.J. Krautler, E. Heinen, M. Polymenidou, C. Bridel, A. Schöldknecht, C. Huber, M.H. Kosco-Valbou, R. Zinkernagel, G. Miele, and A. Aguzzi. 2008. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mipg9. J. Exp. Med. 205:1293–1302. http://dx.doi.org/10.1084/jem.20071019

Laurikkala, J., J. Pisa, H.S. Jung, P. Niininen, M. Mikkola, X. Wang, U. Saarimäki-Kero, J. Galceran, R. Groschedl, and I. Thelesf. 2008. Regulation of hair follicle development by the TNF signal ectodysplasin and its receptor Edar. Development. 129:2541–2553.

Liptay, S., R.M. Schmid, E.G. Nabel, and G.J. Nabel. 1994. Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation. Mol. Cell. Biol. 14:7695–7703.

Lo, J.C., S. Basak, E.S. James, R.S. Quanmo, M.C. Kinless, M.L. Alegre, F. Weihe, G. Franzoso, A. Hoffmann, and Y.X. Fu. 2006. Coordination between NF-κB family members p50 and p52 is essential for mediating LTBR signals in the development and organization of secondary lymphoid tissues. Blood. 107:1048–1055. http://dx.doi.org/10.1182/blood-2005-06-1245

Lopez-Granados, E., J.E. Keenan, M.C. Kinney, H. Leo, N. Jain, C.A. Ma, R. Quinones, E.W. Gelfand, and A. Jain. 2008. A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency. Hum. Mutat. 29:861–868. http://dx.doi.org/10.1002/humu.20740

Matsumoto, M., Y.X. Fu, H. Molina, G. Huang, J. Kim, D.A. Thomas, M.H. Nahm, and D.D. Chaplin. 1997. Distinct roles of lympho toxin α and the type I tumor necrosis factor (TNF) receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells. J. Exp. Med. 186:1997–2004. http://dx.doi.org/10.1084/jem.186.12.1997

Matsushima, A., T. Kaisho, P.D. Kennett, H. Nakano, K. Kuroawa, D. Uchida, K. Takeda, S. Akira, and M. Matsumoto. 2001. Essential role of nuclear factor (NF)-κB-inducing kinase and inhibitor of NF-κB (IkB) kinase α in NF-κB activation through lympho toxin β receptor, but not through tumor necrosis factor receptor I. J. Exp. Med. 193:631–636. http://dx.doi.org/10.1084/jem.193.5.631

McDonald, D.R., J.L. Mooster, M. Reddy, E. Bawle, E. Secord, and R.S. Geha. 2007. Heterozygous N-terminal deletion of IkBα results in functional nuclear factor κB haploinsufficiency, ectodermal dysplasia, and immune deficiency. J. Allergy Clin. Immunol. 120:900–907. http://dx.doi.org/10.1016/j.jaci.2007.08.035

Meitus, R.E. 2003. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3:292–303. http://dx.doi.org/10.1038/nri1054

Miyawaki, S., Y. Nakamura, H. Suzuki, M. Koba, R. Yasumizu, I. Ikehara, and Y. Shibata. 1994. A new mutation, ab, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 24:429–434. http://dx.doi.org/10.1002/eji.1830240224

Napetschnig, J., and H. Wu. 2013. Molecular basis of NF-κB signaling. Annu. Rev. Biophys. 42:443–468. http://dx.doi.org/10.1146/annurev-biophys-083012-130338

Ohnishi, H., R. Miyata, T. Suzuki, T. Nose, K. Kubota, Z. Kato, H. Kaneko, and Y. Shibata. 1994. A new mutation, ab, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 24:429–434. http://dx.doi.org/10.1002/eji.1830240224

Ogawa, M., W. Taguchi, T. Nakajima, T. Tani, T. Asada, M. Fujita, M. Koyama, M. Nakamura, and H. Miki. 2004. A novel transmembrane protein. J. Immunol. 172:538–546. http://dx.doi.org/10.4049/jimmunol.172.4.1538

Okamoto, N., R. Chihara, C. Shimizu, S. Nishimoto, and T. Watanabe. 2007. Distinct roles for lymphotoxin-α and δ in tumor necrosis factor in or ganogenesis and spatial organization of lymphoid tissue. J. Immunol. 178:7579–7588. http://dx.doi.org/10.4049/jimmunol.178.12.7579

Orange, J.S., and R.S. Geha. 2003. Finding NEMO: genetic disorders of NF-κB activation. J. Clin. Invest. 112:983–985. http://dx.doi.org/10.1172/JCI9960
Orange, J.S., A. Jain, Z.K. Ballas, L.C. Schneider, R.S. Geha, and F.A. Boulla. 2004. The presentation and natural history of immunodeficiency caused by nuclear factor-κB essential modulator mutation. J. Allergy Clin. Immunol. 113:725–733. http://dx.doi.org/10.1016/j.jaci.2004.01.762

Orange, J.S., O. Levy, and R.S. Geha. 2005. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-κB activation. Immunol. Rev. 203:21–37. http://dx.doi.org/10.1111/j.0105-2896.2005.00221.x

Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollas. 1996. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397–1411. http://dx.doi.org/10.1084/jem.184.4.1397

Pasparakis, M., L. Alexopoulou, M. Grell, K. Pfenninger, H. Bluethmann, and G. Kollas. 1997. Peyer’s patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc. Natl. Acad. Sci. USA 94:6319–6323. http://dx.doi.org/10.1073/pnas.94.12.6319

Picard, C., J.L. Casanova, and A. Puel. 2011. Stromal cell-immune cell interactions. Annu. Rev. Immunol. 29:23–43. http://dx.doi.org/10.1146/annurev.immunol.29.061509.080011

Pilia, S., A. Carappa, and S.T. Moran. 2005. Marginal zone B cells. Annu. Rev. Immunol. 23:161–196. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115728

Puel, A., C. Picard, C.L. Ku, A. Smahi, and J.L. Casanova. 2004. Inherited disorders of NF-κB-mediated immunity in man. Curr. Opin. Immunol. 16:34–41. http://dx.doi.org/10.1016/j.coi.2003.11.013

Rajewsky, K. 1996. Clonal selection and learning in the antibody system. Nature 381:751–758. http://dx.doi.org/10.1038/381751a0

Rennert, P.D., J.L. Browning, R. Mebius, F. Mackay, and P.S. Hochman. 1996. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 184:1999–2006. http://dx.doi.org/10.1084/jem.184.5.1999

Rennert, P.D., P.S. Hochman, R.A. Flavell, D.D. Chaplin, S. Jayaraman, Rennert, P.D., J.L. Browning, R. Mebius, F. Mackay, and P.S. Hochman. 2009. Roles of IKK-β in the development of the humoral immune response. Nat. Immunol. 10:1193–1199. http://dx.doi.org/10.1038/ni.1789

Rennie, J.M., T. Kawai, K. Izawa, H. Ohnishi, et al. 2013. Autosomal dominant incontinentia pigmenti with X-linked inheritance and disease-modifying NEMO mutations. Cell 154:347–358. http://dx.doi.org/10.1016/j.cell.2013.06.052

Rogers, R.P., L.A. Tran, P.G. Albin, J. Liu, L. Zou, et al. 2009. NFκB2 signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J. Immunol. 182:5439–5445. http://dx.doi.org/10.4049/jimmunol.0801165

Srivastava, A.K., M.C. Durnovszicz, A.J. Hartung, J. Hudson, L.V. Ozuts, D.M. Donovan, C.Y. Cai, and D. Schlesinger. 2001. Ectodermal dysplasias: Al is sufficient to rescue both hair growth and sweat glands in Tabby mice. Hum. Mol. Genet. 10:2973–2981. http://dx.doi.org/10.1093/hmg/10.26.2973

Tsitsikov, E., J.C. Gutierrez-Ramos, and R.S. Geha. 1997. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc. Natl. Acad. Sci. USA 94:10844–10849. http://dx.doi.org/10.1073/pnas.94.20.10844

Tucker, E., K. O'Donnell, M. Fuchsbberger, A.A. Hilton, D. Metcalf, C. Greig, N.A. Sims, J. M. Quinn, W.S. Alexander, D.J. Hilton, et al. 2007. A novel mutation in the Nfkbia gene generates an NF-κB2 “super repressor”. J. Immunol. 179:7514–7522. http://dx.doi.org/10.4049/jimmunol.179.11.7514

van de Pavert, S.A., and R.E. Mebius. 2010. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10:664–674. http://dx.doi.org/10.1038/nri2832

van de Pavert, S.A., B.J. Olivier, G. Goverse, M.F. Vondenhoff, M. Greuter, P. Beke, K. Kusser, U.E. Höpken, M. Lipp, K. Niederreither, et al. 2009. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat. Immunol. 10:1193–1199. http://dx.doi.org/10.1038/ni.1789

Vondenhoff, M.F., M. Greuter, G. Goverse, D. Elewaut, P. Dewint, C.F. Ware, K. Hoorweg, G. Kral, and R.E. Mebius. 2009. LTB4 signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J. Immunol. 182:5439–5445. http://dx.doi.org/10.4049/jimmunol.0801165

Wang, B., H. Fujisawa, L. Zhuang, I. Freed, B.G. Howell, S. Shahid, G.M. Shivji, T.W. Mak, and D.N. Sauder. 2000. CD4+ T helper and CD8+ type 1 cytokotic T cells both play a crucial role in the full development of contact hypersensitivity. J. Immunol. 165:6783–6790. http://dx.doi.org/10.4049/jimmunol.165.12.6783

Weih, F., D. Carrasco, S.K. Durham, D.S. Barton, C.A. Razo, R.P. Ryseck, S.A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB family. Cell 80:331–340. http://dx.doi.org/10.1016/0022-8674(95)90416-6

Weih, D.Z., B.Z. Yilmaz, and F. Weih. 2001. Essential role of RelB in lymphoid development. Annu. Rev. Immunol. 19:1–20. http://dx.doi.org/10.1146/annurev.immunol.19.1.1

Whitby, D., B. Gradman, A. Al-Awadi, M. Green, P. McMillan, G. Cohen, and P. McMillan. 1989. Homeostatic function of the lymphoid follicle: the follicle as a process of self-renewal. Annu. Rev. Immunol. 7:373–401. http://dx.doi.org/10.1146/annurev.immunol.07.102588.002005

Wilder, J.W., R. K∊lmann, U. Schuler, H. Lauterbach, and F. Schon. 2009. Roles of IKK-β, IKK-γ, and p65 in the activation of chemokine receptor 2. J. Interferon Cytokine Res. 29:817–824. http://dx.doi.org/10.1089/jicr.2009.0034

Wright, C.F., T.L. VanArsdale, P.D. Crowe, and J.L. Browning. 1995. The ligands and receptors of the lymphoid system. Curr. Top. Microbiol. Immunol. 198:175–218.